Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Offin

Showing results (41-50 of 88) with videos related to

Pageof 9
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumabMichael Offin, Narek Shaverdian, Andreas Rimner, et al.
Practical Radiation Oncology|October 17, 2020
Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation TherapyAnnemarie F Shepherd, Michelle Iocolano, Jonathan Leeman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 17, 2023
Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesotheliomaJacob Y Shin, Michael Offin, Charles B Simone, et al.
JCO Precision Oncology|September 14, 2020
CNS Metastases in Patients With <i>MET</i> Exon 14-Altered Lung Cancers and Outcomes With CrizotinibMichael Offin, Jia Luo, Robin Guo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 5, 2023
Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiationMaria Thor, Kelly Fitzgerald, Aditya Apte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung CancerNoura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2018
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung CancerKen Suzawa, Michael Offin, Daniel Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical OutcomesMichael Offin, Joseph M Chan, Megan Tenet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2019
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung CancersMorana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, et al.
JCO Precision Oncology|April 9, 2019
Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i>-Mutant Lung CancersMichael Offin, Romel Somwar, Natasha Rekhtman, et al.
Pageof 9

Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumabMichael Offin, Narek Shaverdian, Andreas Rimner, et al.
Practical Radiation Oncology|October 17, 2020
Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation TherapyAnnemarie F Shepherd, Michelle Iocolano, Jonathan Leeman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 17, 2023
Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesotheliomaJacob Y Shin, Michael Offin, Charles B Simone, et al.
JCO Precision Oncology|September 14, 2020
CNS Metastases in Patients With <i>MET</i> Exon 14-Altered Lung Cancers and Outcomes With CrizotinibMichael Offin, Jia Luo, Robin Guo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 5, 2023
Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiationMaria Thor, Kelly Fitzgerald, Aditya Apte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung CancerNoura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2018
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung CancerKen Suzawa, Michael Offin, Daniel Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical OutcomesMichael Offin, Joseph M Chan, Megan Tenet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2019
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung CancersMorana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, et al.
JCO Precision Oncology|April 9, 2019
Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i>-Mutant Lung CancersMichael Offin, Romel Somwar, Natasha Rekhtman, et al.
Pageof 9